P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma
Title:
P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma
Author:
Lonial, Sagar Nooka, Ajay Thulasi, Praneetha Badros, Ashraf Z. Jeng, Bennie Callander, Natalie S. Sborov, Douglas Zaugg, Brian E. Popat, Rakesh Esposti, Simona Degli Baron, January Doherty, Allison Lewis, Eric Opalinska, Joanna Paka, Prani Piontek, Trisha Gupta, Ira Farooq, Asim V. Jakubowiak, Andrzej